COM:SYNDAX
Syndax
- Stock
13.82
−2.33%
4.19
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia ...Show More